Neurogene Inc. Files 8-K: Regulation FD & Financials

Ticker: NGNE · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1404644

Sentiment: neutral

Topics: regulation-fd, financial-statements, exhibits

TL;DR

Neurogene Inc. dropped an 8-K with Reg FD and financials – check it out.

AI Summary

Neurogene Inc. filed an 8-K on November 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is located at 535 W 24th Street, 5th Floor, New York, NY 10011.

Why It Matters

This filing provides important updates on Neurogene Inc.'s regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K for regulatory and financial disclosures, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Neurogene Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What was Neurogene Inc.'s former name?

Neurogene Inc.'s former name was Neoleukin Therapeutics, Inc.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on November 11, 2024.

What is the principal executive office address for Neurogene Inc.?

The principal executive office address for Neurogene Inc. is 535 W 24th Street, 5th Floor, New York, NY 10011.

Under which section of the Securities Exchange Act of 1934 is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-12 06:05:25

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 11, 2024, Neurogene Inc. (the "Company") issued a press release announcing initial efficacy data from the first four participants in the low-dose cohort of its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome and updated safety and tolerability data for the low-dose and high-dose pediatric cohorts from that trial. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. On November 11, 2024, the Company also made available a presentation regarding the clinical data described in the press release referenced above. A copy of the webcast featuring this presentation is available on the Events & Presentations page of the Investors section of the Company's website, and a copy is attached hereto as Exhibit 99.2. The information that is contained in or that can be accessed through the Company's website is not a part of this filing. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 11, 2024 99.2 Corporate Presentation dated November 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: November 12, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing